(Q39370204)

11 September 2017

title

Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient (English)

1 reference

11 September 2017

1 reference

Enrico Roggero

1

1 reference

11 September 2017

Giancarla Busi

series ordinal

2

1 reference

11 September 2017

Antonella Palumbo

series ordinal

3

1 reference

11 September 2017

Augusto Pedrazzini

series ordinal

4

1 reference

11 September 2017

publication date

1 February 2005

1 reference

Journal of Neuro-Oncology

11 September 2017

published in

1 reference

11 September 2017

volume

71

1 reference

11 September 2017

issue

3

1 reference

11 September 2017

page(s)

277-280

1 reference

https://scigraph.springernature.com/pub.10.1007/s11060-004-1719-x

11 September 2017

exact match

0 references

cites work

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://pubmed.ncbi.nlm.nih.gov/15735917

PubMed

reference URL

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/15735917

PubMed

reference URL

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Evidence for a role of EGF receptor in the progression of human lung carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/15735917

PubMed

reference URL

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11060-004-1719-X

1 reference

11 September 2017

1 reference